| Jul 11 |
Amneal to Report Second Quarter 2024 Results on August 9, 2024
|
| Jul 10 |
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
|
| Jul 9 |
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
|
| Jul 1 |
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
|
| Jul 1 |
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
|
| Jun 28 |
Amneal Releases 2023 Environmental, Social and Governance Report
|
| Jun 5 |
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
|
| May 22 |
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
|
| May 20 |
Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX)
|
